Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

New nasal spray delivers antipsychotic medication directly to the brain

A team of neuroscientists and engineers at McMaster University has created a nasal spray to deliver antipsychotic medication directly to the brain instead of having it pass through the body.

16 Jan 2021

Stem cell engineering used to identify gene signaling pathway linked to schizophrenia

Using human-induced pluripotent stem cells engineered from a single family's blood samples, a gene signaling pathway linked to a higher risk for developing schizophrenia was discovered by scientists at The University of Texas Health Science Center at Houston.

21 Dec 2020

UH researcher examines whether early drug intervention can curb weight gain in mentally ill children

A University of Houston pharmacological researcher believes that prescribing the drug Metformin for children and teens as soon as they are diagnosed with mental illnesses, like bipolar disorder and schizophrenia, may save them from gaining an enormous amount of weight.

16 Dec 2020

Researchers identify potential drug target that may improve cognition in people with mental illnesses

More than a dozen drugs are known to treat symptoms such as hallucinations, erratic behaviors, disordered thinking and emotional extremes associated with schizophrenia, bipolar disorder and other severe mental illnesses.

3 Dec 2020

Parasite infection discovery could help develop treatments for neurological disorders

New research into how a common parasite infection alters human behavior could help development of treatments for schizophrenia and other neurological disorders.

16 Nov 2020

New evidence of neurobiological mechanism for hallucinations and delusions found

A new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found evidence of a potential neurobiological mechanism for hallucinations and delusions that fits within the hierarchical model of psychosis and can explain their clinical presentation.

9 Nov 2020

Delirium common after hospital discharge in critically ill COVID-19 patients

Anesthesiologist and other researchers from Michigan Medicine, Ann Arbor, New York Medical College, Valhalla and Center for Consciousness Science, University of Michigan Medical School, Ann Arbor, have reported a case series of critically ill coronavirus disease 2019 (COVID-19) patients who have developed neuropsychological symptoms after having been discharged from the hospital.

8 Nov 2020

Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA or lupus patients

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, discovers that use of hydroxychloroquine, a generic drug, does not cause any significant differences in QTc length or prolonged QTc, key measures of heart rate, in people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

6 Nov 2020

Study sheds new light on the biological base of psychotic symptoms

Anti-NMDAR encephalitis is an autoimmune brain illness that is often mistaken by a psychiatric disorder since it causes psychoses and other behaviour alterations. Despite having these similarities, the illness does not respond to common antipsychotic treatments.

30 Oct 2020

Study sheds light on the biological base of symptoms in autoimmune psychosis

29 Oct 2020

Stanford researchers unravel how a common genetic deletion elevates schizophrenia risk

A common genetic deletion boosts the risk for schizophrenia by 30-fold. Generating nerve cells from people with the deletion has showed Stanford researchers why.

28 Sep 2020

First clinical trial launched to test psilocybin therapy for depression in cancer patients

The first clinical trial to test the safety and feasibility of psilocybin therapy with simultaneous administration and one-on-one patient support to treat depression in cancer patients was launched today by Maryland Oncology Hematology at the Aquilino Cancer Center at Adventist HealthCare Shady Grove Medical Center.

16 Sep 2020

Study examines the side effects of Alzheimer's disease dementia drugs

In a first of its kind study, a University of Houston researcher is examining two common drugs used for dementia in patients with Alzheimer's disease to determine the extent to which they don't mix well together and cause a cascading event of side effects, prompting the need for even more medications.

3 Sep 2020

Antidepressants are not designed for dementia, shows study

Nearly three-quarters of older adults with dementia have filled prescriptions for medicines that act on their brain and nervous system, but aren't designed for dementia, a new study shows.

19 Aug 2020

DNA hypermethylation correlated with reduced amygdala volume in male patients with schizophrenia

Researchers at Kumamoto University, Japan have revealed that DNA methylation occurs in the gene that codes serotonin transporter (SERT), a protein that regulates neurotransmitter transmission, in schizophrenia and bipolar patients.

9 Jul 2020

Antipsychotic medications do not treat young people with early psychosis

Researchers at Orygen have found that some young people with early stage first episode psychosis (FEP) can experience reduced symptoms and improve functioning without antipsychotic medication when they are provided with psychological interventions and comprehensive case management.

17 Jun 2020

Antipsychotic drug clozapine can trigger severe obsessive-compulsive symptoms

A review published in the current issue of Psychotherapy and Psychosomatics analyzes the obsessions and compulsions associated with the use of clozapine, an antipsychotic drug,

11 Jun 2020

Can Chlorpromazine help treat COVID-19?

A new research paper published in the journal L'Encéphale in May 2020 reports on the planned ReCoVery Study, which will examine the possibility of repurposing the antipsychotic drug chlorpromazine for the treatment of COVID-19.

25 May 2020

GlobalData: Patients treated for ICU delirium will increase as COVID-19 outbreak continues

An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.

22 May 2020

Genetic discoveries show promise for developing new treatment targets for schizophrenia

In recent years, genome-wide association studies (GWAS) have identified many different genetic variants associated with schizophrenia.